Trial Outcomes & Findings for The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart Failure (NCT NCT00791843)
NCT ID: NCT00791843
Last Updated: 2019-07-09
Results Overview
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
3 participants
Primary outcome timeframe
baseline, 12, 18, and 30 weeks
Results posted on
2019-07-09
Participant Flow
Data unavailable for study, PI is deceased and all staff associated with study have left the institution.
Participant milestones
| Measure |
GHRH and Placebo
Everyone will receive 12 weeks of GHRH and 12 weeks of Placebo
Growth hormone releasing hormone/ placebo: 12 weeks of drug at max dose of 2mg/day administered in 4 pulses at 11pm, 1am, 3am, and 5am, followed by 6 weeks of washout period, then 12 weeks of placebo or vise versa- 12 weeks of placebo, 6 weeks washout, 12 weeks of drug.
|
|---|---|
|
Overall Study
STARTED
|
0
|
|
Overall Study
COMPLETED
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
The Effect of GHRH Therapy on Myocardial Structure and Function in Congestive Heart Failure
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: baseline, 12, 18, and 30 weeksPopulation: Data unavailable for study, PI is deceased and all staff associated with study have left the institution.
Outcome measures
Outcome data not reported
Adverse Events
GHRH and Placebo
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place